Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells by Pan, Jingxuan
MEETING ABSTRACT Open Access
Overcoming Gleevec-resistance by blocking
oncogene addiction in malignant hematologic cells
Jingxuan Pan
From New development in Hematology and Oncology in 2011
Guangzhou, China. 25-26 December 2011
In some types of tumors, malignant cells are highly
dependent on the constitutive activation of a certain pro-
tein encoded by oncogene, despite existence of additional
carcinogenic genetic changes. This phenomenon is
referred to oncogene addiction. Typical examples include
cytoplasmic tyrosine kinase Bcr-Abl in chronic myeloid
leukemia (CML), receptor tyrosine kinase KIT in sys-
temic mastocytosis and gastrointestinal stromal tumors
(GISTs), and PDGFRa in hypereosinophilic syndrome
(HES). In 2001, the approval of Gleevec (STI571, imatinib
mesylate, Norvartis) by FDA (Food and Drug Adminis-
tration, USA) initiated a revolutionary targeted therapy
against cancer with small molecule tyrosine kinase inhibi-
tors. Gleevec blocks the signaling pathway of tyrosine
kinase by competitively occupying the ATP-binding
pocket of Bcr-Abl, KIT and PDGFRa, and therefore kills
these oncogene-addicted tumor cells. Patients with CML
and HES have gained much better prognosis with the
treatment of Gleevec. However, in some patients (parti-
cularly in accelerating and blast crisis phases), relapse
due to resistance to Gleevec is an emerging problem.
Acquired point mutations within the target genes
(Bcr-Abl, KIT and PDGFRa) are a major mechanism of
resistance to Gleevec in some patients with hematologic
malignance. The mutations are believed to block the
binding of Gleevec to ATP binding pockets of these tyr-
osine kinases. In this case, novel tyrosine kinase inhibi-
tor such as nilotinib and dasatinib (also called the
second-generation of tyrosi n ek i n a s ei n h i b i t o r )h a v e
been shown activity against Gleevec-resistant patients
bearing some point mutations but the “gate-keeper”
mutations (e.g., T315I Bcr-Abl, T674I PDGFRa).
Therefore, development of more novel small molecule
tyrosine kinase inhibitors is still needed.
This talk covered the advance in the field of overcoming
Gleevec resistance in terms of novel compounds and strate-
geies. Pan J et al reported that EXEL-0862 is effective
against Gleevec-resistant D816V KIT and T674I PDGFRa
(2007). Recently, in vitro and animal data supported that
several novel tyrosine kinase inhibitors including (but not
limited) AP24534 (ponatinib) and DCC-2036 have been
demonstrated effective against T315I Bcr-Abl. However,
the efficacy and safety of these pounds (EXEL-0862,
AP24534 and DCC-2036) in patients remains to be defined.
An alternative approach for overcoming Gleevec-resistance
is to decrease the expression of “addicted” oncogenes,
which are driving forces of the tumor cells, to kill the malig-
nant cells. Our group discovered several compounds which
are effective against Gleevec-resistant tumor cells regardless
of resistance to imatinib. The compounds kill cells harbor-
ing gate-keeper mutants of tyrosine kinases by lowering the
expression of the oncoproteins (Bcr-Abl, KIT and
PDGFRa). Examples include triptolide, pristimerin and
SNS-032 (transcription inhibitors), homoharringtonine (a
translation inhibitor), and celastrol (a hsp90 inhibitor).
In summary, Gleevec-resistance remains a challenge in
leukemia. The findings from us and others suggest that
several aforementioned compounds are promising
agents to overcome Gleevec resistance, and warrant
clinical trials.
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